FDA clears Mylan's generic transdermal system for hypertension

Kaitlyn Dmyterko | | Health Imaging | Diagnostic Imaging
The FDA has given the green light to Mylan Technologies' abbreviated new drug application for its Clonidine Transdermal System, a generic version of the Catapres-TTS system (Boehringer Ingelheim) used to treat hypertension.

Pittsburgh-based Mylan said the Clonindine Transdermal System will be available in 0.1 mg per day, 0.2 mg per day and 0.3 mg per day dosages and is currently available for shipment.

According to Mylan, the Clonindine Transdermal System saw $313 million in sales for 12 months, which ended March 31.

Kaitlyn Dmyterko

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.